Johnstone RW, Frew AJ, Smyth MJ (2008) The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 8:782–798. https://doi.org/10.1038/nrc2465

Article  CAS  Google Scholar 

Ashkenazi A (2002) Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2:420–430. https://doi.org/10.1038/nrc821

Article  CAS  Google Scholar 

Lemke J, von Karstedt S, Zinngrebe J, Walczak H (2014) Getting TRAIL back on track for cancer therapy. Cell Death Differ 21:1350–1364. https://doi.org/10.1038/cdd.2014.81

Article  CAS  Google Scholar 

Holland PM (2014) Death receptor agonist therapies for cancer, which is the right TRAIL? Cytokine Growth Factor Rev 25:185–193. https://doi.org/10.1016/j.cytogfr.2013.12.009

Article  CAS  Google Scholar 

Kelley SK, Harris LA, Xie D, Deforge L, Totpal K, Bussiere J, Fox JA (2001) Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 299:31–38

CAS  Google Scholar 

Xiang H, Nguyen CB, Kelley SK, Dybdal N, Escandón E (2004) Tissue distribution, stability, and pharmacokinetics of Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in human colon carcinoma COLO205 tumor-bearing nude mice. Drug Metab Dispos 32:1230–1238. https://doi.org/10.1124/dmd.104.000323

Article  CAS  Google Scholar 

Graves JD, Kordich JJ, Huang TH, Piasecki J, Bush TL, Sullivan T, Foltz IN, Chang W, Douangpanya H, Dang T, O’Neill JW, Mallari R, Zhao X, Branstetter DG, Rossi JM, Long AM, Huang X, Holland PM (2014) Apo2L/TRAIL and the death receptor 5 agonist antibody AMG 655 cooperate to promote receptor clustering and antitumor activity. Cancer Cell 26:177–189. https://doi.org/10.1016/j.ccr.2014.04.028

Article  CAS  Google Scholar 

Tuthill MH, Montinaro A, Zinngrebe J, Prieske K, Draber P, Prieske S, Newsom-Davis T, von Karstedt S, Graves J, Walczak H (2015) TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells. Oncogene 34:2138–2144. https://doi.org/10.1038/onc.2014.156

Article  CAS  Google Scholar 

Phillips DC, Buchanan FG, Cheng D, Solomon LR, Xiao Y, Xue J, Tahir SK, Smith ML, Zhang H, Widomski D, Abraham VC, Xu N, Liu Z, Zhou L, DiGiammarino E, Lu X, Rudra-Ganguly N, Trela B, Morgan-Lappe SE (2021) Hexavalent TRAIL fusion protein eftozanermin alfa optimally clusters apoptosis-Inducing TRAIL receptors to induce on-target antitumor activity in solid tumors. Cancer Res 81:3402–3414. https://doi.org/10.1158/0008-5472.can-20-2178

Article  CAS  Google Scholar 

Carneiro BA, El-Deiry WS (2020) Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol 17:395–417. https://doi.org/10.1038/s41571-020-0341-y

Article  Google Scholar 

Danish L, Imig D, Allgöwer F, Scheurich P, Pollak N (2018) Bcl-2-mediated control of TRAIL-induced apoptotic response in the non-small lung cancer cell line NCI-H460 is effective at late caspase processing steps. PLoS ONE 13:e0198203. https://doi.org/10.1371/journal.pone.0198203

Article  CAS  Google Scholar 

Zhang L, Fang B (2005) Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 12:228–237. https://doi.org/10.1038/sj.cgt.7700792

Article  CAS  Google Scholar 

Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ, Huang DC, Hymowitz SG, Jin S, Khaw SL, Kovar PJ, Lam LT, Lee J, Maecker HL, Marsh KC, Mason KD, Mitten MJ, Nimmer PM, Oleksijew A, Park CH, Park CM, Phillips DC, Roberts AW, Sampath D, Seymour JF, Smith ML, Sullivan GM, Tahir SK, Tse C, Wendt MD, Xiao Y, Xue JC, Zhang H, Humerickhouse RA, Rosenberg SH, Elmore SW (2013) ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19:202–208. https://doi.org/10.1038/nm.3048

Article  CAS  Google Scholar 

Tahir SK, Smith ML, Solomon LR, Zhang H, Xue JC, Xiao Y, Cheng D, Buchanan G, Morgan-Lappe S, Phillips DC (2017) ABBV-621 is a novel and potent TRAIL receptor agonist fusion protein that induces apoptosis alone and in combination with navitoclax and venetoclax in hematological tumors. Blood 130:2812–2812. https://doi.org/10.1182/blood.V130.Suppl_1.2812.2812

Article  Google Scholar 

LoRusso P, Ratain MJ, Doi T, Rasco DW, de Jonge MJA, Moreno V, Carneiro BA, Devriese LA, Petrich A, Modi D, Morgan-Lappe S, Nuthalapati S, Motwani M, Dunbar M, Glasgow J, Medeiros BC, Calvo E (2022) Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study. Invest New Drugs 40:762–772. https://doi.org/10.1007/s10637-022-01247-1

Article  CAS  Google Scholar 

Tahir SK, Calvo E, Carnero BA, Yuda J, Shreenivas A, Jongen-Lavrencic M, Gort E, Ishizawa K, Morillo D, Biesdorf C, Smith M, Cheng D, Motwani M, Sharon D, Uziel T, Modi DA, Buchanan FG, Morgan-Lappe S, Medeiros BC, Phillips DC (2023) Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia. Blood 141:2114–2126. https://doi.org/10.1182/blood.2022017333

Article  CAS  Google Scholar 

Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355:1041–1047. https://doi.org/10.1016/s0140-6736(00)02034-1

Article  CAS  Google Scholar 

Liu H, Michmerhuizen MJ, Lao Y, Wan K, Salem AH, Sawicki J, Serby M, Vaidyanathan S, Wong SL, Agarwal S, Dunbar M, Sydor J, de Morais SM, Lee AJ (2017) Metabolism and disposition of a novel B-cell lymphoma-2 inhibitor venetoclax in humans and characterization of Its unusual metabolites. Drug Metab Dispos 45:294–305. https://doi.org/10.1124/dmd.116.071613

Article  CAS  Google Scholar 

Liu L (2015) Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins. J Pharm Sci 104:1866–1884. https://doi.org/10.1002/jps.24444

Article  CAS  Google Scholar 

Chen X, Zaro JL, Shen WC (2012) Pharmacokinetics of recombinant bifunctional fusion proteins. Expert Opin Drug Metab Toxicol 8:581–595. https://doi.org/10.1517/17425255.2012.673585

Article  CAS  Google Scholar 

Vugmeyster Y, Xu X, Theil FP, Khawli LA, Leach MW (2012) Pharmacokinetics and toxicology of therapeutic proteins: advances and challenges. World J Biol Chem 3:73–92. https://doi.org/10.4331/wjbc.v3.i4.73

Article  Google Scholar 

Zhao L, Ren TH, Wang DD (2012) Clinical pharmacology considerations in biologics development. Acta Pharmacol Sin 33:1339–1347. https://doi.org/10.1038/aps.2012.51

Article  CAS  Google Scholar 

Keizer RJ, Huitema AD, Schellens JH, Beijnen JH (2010) Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 49:493–507. https://doi.org/10.2165/11531280-000000000-00000

Article  CAS  Google Scholar 

Liu L (2018) Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins. Protein Cell 9:15–32. https://doi.org/10.1007/s13238-017-0408-4

Article  CAS  Google Scholar 

Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, McKeegan E, Salem AH, Zhu M, Ricker JL, Blum W, DiNardo CD, Kadia T, Dunbar M, Kirby R, Falotico N, Leverson J, Humerickhouse R, Mabry M, Stone R, Kantarjian H, Letai A (2016) Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov 6:1106–1117. https://doi.org/10.1158/2159-8290.CD-16-0313

Article  CAS  Google Scholar 

Salem AH, Agarwal SK, Dunbar M, Enschede SL, Humerickhouse RA, Wong SL (2017) Pharmacokinetics of venetoclax, a novel BCL-2 inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia or non-hodgkin lymphoma. J Clin Pharmacol 57:484–492. https://doi.org/10.1002/jcph.821

Article  CAS  Google Scholar 

Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, Kipps TJ, Anderson MA, Brown JR, Gressick L, Wong S, Dunbar M, Zhu M, Desai MB, Cerri E, Heitner Enschede S, Humerickhouse RA, Wierda WG, Seymour JF (2016) Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med 374:311–322. https://doi.org/10.1056/NEJMoa1513257

Article  CAS  Google Scholar 

Chirmule N, Jawa V, Meibohm B (2012) Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy. AAPS J 14:296–302. https://doi.org/10.1208/s12248-012-9340-y

Article  CAS  Google Scholar